594 related articles for article (PubMed ID: 29996816)
1. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
Lambert LK; Balneaves LG; Howard AF; Gotay CC
Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
[TBL] [Abstract][Full Text] [Related]
3. Provider perspectives on patient-provider communication for adjuvant endocrine therapy symptom management.
Turner K; Samuel CA; Donovan HA; Beckjord E; Cardy A; Dew MA; van Londen GJ
Support Care Cancer; 2017 Apr; 25(4):1055-1061. PubMed ID: 27864628
[TBL] [Abstract][Full Text] [Related]
4. Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
Lambert LK; Balneaves LG; Howard AF; Chia SLK; Gotay CC
Curr Oncol; 2021 Apr; 28(2):1472-1482. PubMed ID: 33918560
[TBL] [Abstract][Full Text] [Related]
5. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
[TBL] [Abstract][Full Text] [Related]
6. Provider perspectives on barriers and facilitators to adjuvant endocrine therapy-related symptom management.
Samuel CA; Turner K; Donovan HAS; Beckjord E; Cardy A; Dew MA; van Londen GJ
Support Care Cancer; 2017 Dec; 25(12):3723-3731. PubMed ID: 28681126
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
Clancy C; Lynch J; OConnor P; Dowling M
Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
[TBL] [Abstract][Full Text] [Related]
8. Religion and spirituality: their role in the psychosocial adjustment to breast cancer and subsequent symptom management of adjuvant endocrine therapy.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2021 Jun; 29(6):3017-3024. PubMed ID: 33034750
[TBL] [Abstract][Full Text] [Related]
9. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
[TBL] [Abstract][Full Text] [Related]
10. Exploring the role of social support and adjuvant endocrine therapy use among breast cancer survivors.
Toledo G; Ochoa CY; Farias AJ
Support Care Cancer; 2020 Jan; 28(1):271-278. PubMed ID: 31037379
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.
van Londen GJ; Donovan HS; Beckjord EB; Cardy AL; Bovbjerg DH; Davidson NE; Morse JQ; Switzer GE; Verdonck-de Leeuw IM; Dew MA
Oncol Nurs Forum; 2014 Nov; 41(6):660-8. PubMed ID: 25355021
[TBL] [Abstract][Full Text] [Related]
12. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Paranjpe R; John G; Trivedi M; Abughosh S
Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
[TBL] [Abstract][Full Text] [Related]
14. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
[TBL] [Abstract][Full Text] [Related]
15. Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.
Labonté M; Guillaumie L; Dionne A; Dorval M; Nabi H; Lemieux J; Provencher L; Lauzier S
Res Social Adm Pharm; 2020 Dec; 16(12):1724-1736. PubMed ID: 32205070
[TBL] [Abstract][Full Text] [Related]
16. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
[TBL] [Abstract][Full Text] [Related]
17. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
[TBL] [Abstract][Full Text] [Related]
18. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
[TBL] [Abstract][Full Text] [Related]
19. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy use among Appalachian breast cancer survivors.
Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
